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Abstract 
Background: Patients who undergo radiotherapy to treat head and neck cancer can present with several symp-
toms, including oral ones. The symptoms are usually assessed using instruments to evaluate quality of life. However, 
these instruments do not really assess oral health outcomes and their functional implications. The VHNSS 2.0 instru-
ment was developed to be used with head and neck cancer patients, and has recently been translated and culturally 
adapted to be used in Brazil. The purpose of the study was to evaluate the psychometric properties of the VHNSS 2.0 
Brazilian Portuguese version.
Methods: Three assessment instruments, the Brazilian Portuguese versions of EORTC QLQ-C30, EORTC H&N 35 and 
VHNSS 2.0, were answered by 241 head and neck cancer patients, of whom 47 were submitted to the test retest in 
5–16 days. The construct validity was assessed through convergent validation (assuming correlations between VHNSS 
2.0 and EORTC), and known group analysis (radiotherapy time, site of tumor, staging and surgery). Reliability was 
evaluated by means of Cronbach’s alpha and test retest using the intraclass correlation coefficient.
Results: 241 head and neck cancer patients, median age 58.8, were included in this study. Hypothesized correla-
tions were confirmed, the comparison among the groups showed differences in most of the domains. Reliability for 
the domains of swallowing solids, dry mouth, mouth pain, mucus, voice, pain and taste/smell presented Cronbach’s 
alpha values from 0.858 to 0.735 and for the domains of nutrition, swallowing liquids and teeth, 0.618, 0.620 and 0.670 
respectively. The test–retest reliability, for the domains of the VHNSS 2.0, measured using intraclass correlation coef-
ficient, ranged from 0.372 to 0.854.
Conclusion: The VHNSS 2.0 Brazilian Portuguese version presented good results for the convergent validation and 
known-group analyses. It also showed reliability for the Cronbach´s alpha and test retest for most domains.
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Background
Head and neck cancers (HNC) include tumors that affect 
important anatomical structures, such as the lips, oral 
cavity, oropharynx, nasopharynx, hypopharynx, larynx, 
nasal cavity and paranasal sinuses, thyroid gland and sali-
vary glands [1]. Patients undergoing treatment in these 
regions often have sequelae due to the involvement of 
vital structures, either due to treatment or disease site. 
In addition, a considerable number of survivors have 
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adverse effects that may be related to early or delayed 
treatment [2].
After diagnosis, treatment often results in significant 
changes, which can be simply subjective for example, pain 
or functional changes [3] such as breathing, chewing, sali-
vary flow, swallowing and speaking [4]. The assessment 
of symptoms in patients with HNC can be performed 
using specific instruments, but often, the symptoms are 
addressed by quality-of-life (QoL) assessment instru-
ments [5]. It is noteworthy that the instruments avail-
able and most commonly used for patients with HNC do 
not include some important and frequent oral changes. 
Thus far, some changes have been rarely reported and 
described, including those related to dental health, 
mucosal sensitivity and trismus, and their functional 
implications are not addressed very often either [6].
Considering these aspects, the initial development of 
the Vanderbilt Head and Neck Symptom Survey version 
2.0 (VHNSS 2.0), which is a subjective symptom assess-
ment instrument for HNC patients proposed for use in 
clinical practice to screen for oral health outcomes, was 
published in 2012 [6]. It was found to be able to detect the 
prevalence and severity of oral problems in HNC patients 
who had undergone radiation [6]. The psychometric pro-
prieties were tested in the same population presenting 
Cronbach’s alpha ranging from 0.70 to 0.95 [7]. Further-
more, the instrument could detect changes over time in 
this population [8]. Moreover, in a recent publication, 
the National Cancer Institute (NCI) recommended that a 
group of symptoms, including swallowing, oral pain, skin 
changes, dry mouth, dental health, trismus, taste, excess 
mucus/saliva, shoulder movement, voice/hoarseness and 
some QoL domains (social and functional), should be 
evaluated in clinical trials because they are relevant for 
most HNC patients [9].
VHNSS 2.0 was developed in English and has recently 
been translated and culturally adapted into Brazilian Por-
tuguese [10]. This study aimed to evaluate the psycho-




This was a descriptive, cross-sectional study with an 
assessment instrument validation methodology, using the 
STROBE guidelines for reporting observational studies 
[11], carried out at the Department of Head and Neck Can-
cer, Barretos Cancer Hospital, São Paulo, Brazil. Patients 
were included from September 2013 to August 2014.
Study population
The population comprised patients older than 18 with a 
history of HNC (oral cavity, hypopharynx, oropharynx 
and larynx), whose radiotherapy treatment ended 
6 months or more prior to the study, and who could read. 
Important cognitive changes that would prevent partici-
pants from responding to the assessment instruments 
were considered as exclusion criteria. These cognitive 
changes were identified by means of medical records and 
the perception of the researcher.
Ethical statement
This study was approved by the Research Ethics Commit-
tee of the Barretos Cancer Hospital (644/2012) and was 
developed according to the ethical principles of the Dec-
laration of Helsinki and National Health Council (Brazil), 
Resolution 466/2012. All subjects participated voluntar-
ily and signed an informed consent form.
Data collection
This step was performed by a single properly trained 
researcher (EMB) who identified eligible patients and 
invited them to participate. Socio-demographic charac-
teristics, such as gender, race, civil status and education 
were self-reported and clinical characteristics (histologi-
cal type, staging, tumor site, and treatment/s) were col-
lected by means of medical records. The instruments 
were applied individually in a reserved environment, and 
each patient was given a choice between self-adminis-
tering the instrument and having the instrument applied 
by the researcher. When applied by the interviewer, the 
questions and answers were read and care was taken 
not to provide any explanations. If the patients did not 
respond for any reason, the item was left blank and 
recorded as a non-response. The time required for com-
pleting the instrument was measured using a stopwatch.
Data collection instruments
Three instruments were used: the Brazilian Portuguese 
versions of the instruments Vanderbilt Head and Neck 
Symptom Survey version 2.0 [6], EORTC QLQ C30 [12] 
and EORTC H&N 35 [13].
Vanderbilt Head and Neck Symptom Survey version 2.0 
(VHNSS 2.0)
It is an instrument developed specifically for patients 
with HNC and is intended to evaluate symptoms and oral 
changes in patients who have undergone radiotherapy. 
It was developed in 2012 [6] and comprises 10 domains 
and three single items: nutrition (four items), swallowing 
solids (eight items), swallowing liquids (two items), dry 
mouth (five items), mouth pain (six items), general pain 
(three items), mucus (four items), voice/communication 
(three items), hearing (one item), taste/smell (six items), 
teeth (four items), neck range of motion (one item) 
and trismus (one item). Response choices range from 0 
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(none) to 10 (severe) so that, the higher the score is, the 
greater the intensity of symptoms will be. The mean of 
each domain is calculated only if there is a response for at 
least half of the items. Items receiving a “not applicable” 
response are treated as a non-response in the score cal-
culation. The time reference is in relation to the previous 
week.
EORTC QLQ C 30
It is a questionnaire evaluating cancer-specific QoL 
that has been previously validated for use in Brazil [14, 
15] and comprises 30 items, including five functional 
scales, three symptom scales, an overall health scale and 
some individual items related to symptoms commonly 
reported by cancer patients, with responses graded on a 
Likert scale varying from 0 to 4 points. For QoL-related 
and overall health status items, the responses are graded 
on a 7-point Likert scale. Scores range from 0 to 100, 
where 0 represents the worst health status and 100 repre-
sents the best health status; this is in contrast to the way 
in which the symptom scales work, where higher scores 
represent a higher level of symptoms and a worse QoL 
[12]. Cronbach’s alpha in this study was calculated to be 
0.895.
EORTC H&N 35
The EORTC H&N 35 [13] was developed by the Euro-
pean Organization for Research and Treatment of Cancer 
(EORTC). It is specific for patients with HNC and is com-
plementary to QLQ C30. It contains 35 items that evalu-
ate seven domains: pain, swallowing, senses (taste and 
smell), speech, social eating, social contact, and sexuality, 
as well as single specific items related to dental problems, 
trismus, dry mouth, sticky saliva, coughing, feeling ill, 
use of pain killers, use of nutritional supplements, use of 
feeding tube and weight gain/loss. Thirty of the responses 
were graded on a Likert scale ranging from 1 to 4, and 
five questions required a yes or no response. High scores 
represent high symptomatology. The questions are 
related to events in the previous week. Cronbach’s alpha 
in this study was calculated to be 0.885.
Validation process stages
Psychometric properties
Internal consistency was measured using Cronbach’s α, 
considering a value between 0.70 and 0.95 as acceptable 
[16].
The reproducibility of the VHNSS 2.0 instrument was 
evaluated by the ICC, considering values ≥0.7 as accept-
able [16]. This was performed over a period of 1–2 weeks, 
which could vary up to 2 days, in the same setting as the 
baseline measures. Once the subjects were follow up 
patients and did not have to come back to the hospital 
very often, the ones included were the ones who came, 
for any reason, within this time interval. As the retest 
should be performed on clinically stable patients, the 
performance status (ECOG) was evaluated at both time 
points to confirm clinical stability.
Construct validity was assessed using hypothesis test-
ing. For convergent validity, correlations were assumed 
to exist between scores for nutrition, swallowing solids, 
swallowing liquids, dry mouth, mouth pain, voice, gen-
eral pain, taste/smell and trismus measured by VHNSS 
2.0, and scores for social eating, swallowing, dry mouth, 
pain, speech problems, pain, sense problems and open-
ing mouth as measured by EORTC H&N 35. Correla-
tions between the general pain and mouth pain domains 
of VHNSS 2.0 and pain domain of EORTC QLQ C-30 
were also assumed. Correlations >0.4 were considered as 
acceptable [17].
In the known-groups analysis, the groups were com-
pared using the mean (standard deviation) symptoms 
of each domain as measured by VHNSS 2.0, to assess 
whether the instrument could discriminate between the 
patient groups. It was assumed that those who com-
pleted radiotherapy between 6 and 12  months versus 
>12  months; those who underwent surgical treatment 
versus no surgical treatment, and those diagnosed as 
stage I/II versus III/IV would all differ regarding the 
scores of the instrument. An additional exploratory 
analysis was performed to assess whether the instru-
ment could discriminate among groups of patients with 
diseases at different sites, comparing those with diseases 
in the oral cavity/oropharynx to those with disease in the 
hypopharynx/larynx.
These differences were assumed, since the scores of 
symptom items measured using VHNSS 2.0 tend to 
improve over time, considering early, mid and late recov-
ery, post chemo-radiation [18]. Furthermore, patients 
with advanced stages were expected to present higher 
symptom scores [13, 19]. It was also expected that 
patients who had undergone surgery would present prob-
lems related to the procedure, such as mouth opening 
[20]. Moreover, the differences among sites were assumed 
because oral cancer patients may present problems with 
teeth, trismus and pain; pharynx cancer patients usually 
present alterations related to swallowing, social eating 
and stick saliva, whereas larynx cancer patients report 
higher scores in the voice and cough scales [13].
Missing information was evaluated considering the 
number of non-responses per item, with values of up to 
4 % being considered acceptable [17].
Statistical analyses
All the data were analyzed using the IBM SPSS Statistic 
21 statistical program and Software R program, adopting 
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a 5 % significance level. Cronbach’s alpha coefficient was 
used to calculate internal consistency, and the ICC was 
used for test–retest evaluation. Convergent validity cor-
relations were evaluated using Pearson’s correlation coef-
ficient. For the known-groups analysis, the groups were 
compared using the nonparametric Mann–Whitney 
U-test.
The sample size was calculated using the Cronbach’s 
alpha coefficient expected by the researcher (α  =  0.7), 
under the null hypothesis (α  =  0.6), considering a 5  % 
significance level, and 85 % test power [21, 22], resulting 
in a sample of 224 patients. For the retest, the intraclass 
correlation coefficient (ICC) expected by the researcher 
(ρ = 0.85) was used, under the null hypothesis (ρ = 0.7), 
with a 5 % significance level, and 85 % test power, result-
ing in 47 patients.
Results
Two hundred sixty-five patients were invited to partici-
pate in the study, of whom 19 refused, and five could not 
respond to the instrument because they presented with 
important cognitive changes, leaving 241 participants. 
The median age of the participants was 58.8 (range 33.49–
88.55) years. All the patients preferred the interview to be 
applied by the researcher, and the median time of appli-
cation of VHNSS 2.0 and EORTC H&N 35 was 8 (range 
4–17) and 6 (range 2–17) minutes, respectively. The 
median time between the end of radiotherapy and inter-
view was 2 (range 0–23) years. The socio-demographic 
and clinical characteristics are described in Table 1.
Descriptive analysis of the VHNSS 2.0 items
Table  2 shows the frequency and severity of symptoms 
measured by the VHNSS 2.0 instrument, graded as no 
symptoms (0), mild (1–4), moderate (5–6) and severe 
(>7) [23]. Items from the swallowing solids, dry mouth, 
mucus, taste/smell, voice and teeth domains had higher 
percentages of moderate to severe scores. The percentage 
of missing items was 0.21 % (25/11568).
In Table  3, it can be observed that the most affected 
domain was dry mouth, with a mean (standard devia-
tion [SD]) score of 3.38 (2.72), followed by swallowing 
solids (mean  =  2.63, SD  =  2.22), voice (mean  =  2.59, 
SD = 2.60) and teeth (mean = 2.37, SD = 2.28. The least 
affected domains were mouth pain, swallowing liquids 
and pain, with mean (SD) scores of 0.76 (1.52), 0.86 (1.74) 
and 1.13 (2.10), respectively.
Construct validity
Convergent validity
As expected, the hypothetical correlations between the 
VHNSS 2.0 and EORTC QLQ C30, and VHNSS 2.0 and 




 Female 32 (13.3)
 Male 209 (86.7)
Race
 White 144 (59.8)
 Black 16 (6.6)
 Other races 81 (33.6)
Civil status
 Single 32 (13.3)
 Married 164 (68.0)
 Separated/divorced 32 (13.3)
 Widowed 13 (5.4)
Education
 <8 years 161 (67.1)
 ≥8 to <11 years 26 (10.8)
 ≥ 12 years 53 (22.1)
Family monthly incomea
 <1 11 (4.7)
 ≥1 and <3 173 (73.3)
 ≥3 and <6 40 (16.9)
 ≥6 12 (5.1)
Professional statusb
 Inactive 183 (75.9)
 Active 58 (24.1)
Teeth
 No 92 (38.2)
 Yes 149 (61.8)
Histological type
 SCC 234 (97.1)
 Other 7 (2.9)
TNM
 0 1 (0.4)
 I 37 (15.9)
 II 32 (13.7)
 III 77 (33)
 IV 86 (36.9)
Tumor site
 Oral cavity 57 (23.7)
 Hypopharynx 21 (8.7)
 Oropharynx 61 (25.3)
 Larynx 102 (42.3)
ECOG
 0 172 (71.4)
 1 67 (27.8)
 2 2 (0.8)
Type of treatment
 Radiation 40 (16.39)
 Radiation + chemotherapy 85 (35.26)
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EORTC H&N 35 domains were confirmed, presenting 
correlations >0.4 (Table 4).
Known‑groups validity
The Known-groups analysis, considering time of therapy 
completion, stage of disease, tumor site and surgical or 
non-surgical treatment, showed that the instrument 




Most domains had Cronbach’s α values ≥0.70, except for 
nutrition (α = 0.618), swallowing liquids (α = 0.620) and 
teeth (α = 0.670) (Table 2).
Test–retest reproducibility
This evaluation was performed with 47 patients, and 
showed values ≥0.7 for the swallowing solids, swallow-
ing liquids, dry mouth, mucus, teeth, speech, general 
pain and trismus domains and equal to 0.6 for the nutri-
tion, mouth pain and taste/smell domains. The coef-
ficients were low for neck and hearing items, 0.478 and 
0.372, respectively (Table  6). Functionality, as measured 
by ECOG, remained stable across the two-time points 
(Kappa = 0.827; p < 0.001).
Discussion
This study described stages in the validation process 
of the Brazilian Portuguese version of VHNSS 2.0, in 
a sample of patients with HNC being followed up. The 
results indicated that VHNSS 2.0 is an instrument with 
the potential to evaluate severity of oral changes associ-
ated with treatment, which includes radiotherapy of the 
head and neck region, for use in clinical practice and/or 
research in this population.
In general, the sociodemographic and clinical char-
acteristics are representative of the study population 
because studies in the Brazilian population indicate 
that HNC prevalence is higher in men with low income, 
advanced-stage disease and squamous cell carcinoma 
histological type [24].
In this study, 161 (67.1  %) participants had less than 
8  years of education, and all the subjects opted for the 
VHNSS 2.0 to be applied by the interviewer. However, 
the use of VHNSS 2.0 is feasible because the median time 
to respond, when applied by an interviewer, was 8  min 
(range 4–17 min), compared with 6 min (2–17 min) for 
EORTC H&N 35 and QLQ C30. In Brazil, it is known 
that there is a preference for assessment instruments to 
be applied by the interviewer [14]. Data from the valida-
tion process of the original version reported a time less 
than 10 min when self-administered [6]. In this study, the 
median time between the end of radiotherapy and the 
interview was 2 (range 0–23) years, whereas the median 
time of the original study was 1 (range 0–13) year [6]. 
Besides that, the VHNSS 2.0 has been tested before, dur-
ing and up to 42 weeks post treatment [8]. Also notewor-
thy is that the number of items without responses was 
small and within the expected level.
When the frequency and severity of symptoms meas-
ured by VHNSS 2.0 were evaluated, the swallowing 
solids, dry mouth, mucus, taste/smell, voice and teeth 
domains had higher percentages of severe scores (score 
>7). For the dry mouth and difficulty chewing due to 
teeth/dentures items, 38.6 and 24.8 % of the population 
had severe levels (scores >7), respectively, compared 
with 36 and 16.4  % of patients, respectively, in a study 
published by Kolnick et  al. [23]. The data of the valida-
tion process study of the original instrument showed sig-
nificant percentages of moderate to severe scores in the 
swallowing solids, dry mouth, mucus, taste/smell, voice 
and general pain domains (>4) [7]. The presence of symp-
toms at considerable levels and severity reflects the need 
for monitoring, even in patients whose treatment is com-
pleted. The use of assessment instruments can provide 
useful information to help health professionals in patient 
care [5].
Regarding construct validity, the instrument was com-
pared with the EORTC QLQ C30 and H&N 35, which, 
although evaluate QoL, have specific functional and 
symptom domains and are instruments with adequate 
psychometric properties for patients with HNC [25]. 
Thus, one might expect to find correlations higher than 
0.4 between the items and assumed domains, and this 
has been confirmed, with the lowest correlation being 
0.418 (VHNSS mouth pain × EORTC H&N 35 social eat-
ing) and the highest correlation being 0.756 (VHNSS 2.0 
swallowing solids × H&N 35 swallowing), showing com-
mon features among these instruments.
It was not possible to discriminate among patient 
groups regarding any of the situations tested in four 
domains (swallowing liquid, mucus, hearing and neck). 
SSC squamous cell carcinoma, TNM classification of malignant tumors, ECOG 
Eastern Cooperative Oncology Group
a Brazilin minimum wages (R$)
b Professionally active: had a job, inactive: unemployed, retired, or on sick leave
Table 1 continued
Characteristics N (%)
 Radiation + chemotherapy + surgery 51 (21.16)
 Radiation + surgery 65 (26.97)
Full denture
 No 107 (44.4)
 Yes 134 (55.6)
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Table 2 Frequency and severity of scores measured by VHNSS 2.0 and Cronbach’s alpha
Domains/items  
descriptions










n (%) n (%) n (%) n (%) (95 % CI)
Nutrition 0.618 (0.532–0.691)
 Weight loss 239 (2) 201 (84.1) 25 (10.5) 7 (2.9) 6 (2.5) 0.571
 Appetite loss 241 (0) 190 (78.8) 15 (6.2) 20 (8.2) 16 (6.6) 0.542
 Supplement use 240 (1) 187 (77.9) 5 (2.1) 12 (5.0) 36 (15.0) 0.656
 Trouble maintaining 
weight
241 (0) 188 (78.0) 17 (7.1) 20 (8.3) 16 (6.6) 0.418
Swallowing solids 0.858 (0.829–0.883)
 Trouble eating solids 241 (0) 59 (24.5) 47 (19.5) 69 (28.6) 66 (27.4) 0.842
 Food gets stuck in 
mouth
241 (0) 125 (51.9) 40 (16.6) 50 (20.7) 26 (10.8) 0.831
 Food gets stuck in 
throat
241 (0) 129 (53.5) 53 (22.0) 34 (14.1) 25 (10.4) 0.837
 Chokes on solids 241 (0) 158 (65.6) 44 (18.3) 27 (11.2) 12 (5.0) 0.842
 Cough after swallow 241 (0) 170 (70.5) 38 (15.8) 23 (9.5) 10 (4.1) 0.856
 Swallowing takes effort 241 (0) 146 (60.6) 41 (17.0) 32 (13.3) 22 (9.1) 0.829
 Eating takes longer 240 (1) 106 (44.2) 40 (16.7) 57 (23.8) 37 (15.4) 0.823
 Sensitivity to acidic, 
spicy or hot foods
241 (0) 118 (49.0) 36 (14.9) 37 (15.4) 50 (20.7) 0.862
Swallowing liquids 0.620 (0.511–0.705)
 Trouble drinking liquids 241 (0) 204 (84.6) 20 (8.3) 10 (4.1) 7 (2.9) _
 Chokes on liquids 241 (0) 185 (76.8) 36 (14.9) 12 (5.0) 8 (3.3) _
Dry mouth 0.840 (0.806–0.870)
 Dry mouth 241 (0) 47 (19.5) 45 (18.7) 56 (23.2) 93 (38.6) 0.803
 Difficulty chewing 240 (1) 92 (38.3) 43 (17.9) 46 (19.2) 59 (24.6) 0.779
 Difficulty sleeping 241 (0) 171 (71.0) 29 (12.0) 17 (7.1) 24 (10.0) 0.853
 Difficulty speaking 240 (1) 122 (50.8) 38 (15.8) 39 (16.3) 41 (17.1) 0.804
 Sensitivity to dryness 241 (0) 123 (51.0) 39 (16.2) 44 (18.3) 35 (14.5) 0.791
Mouth pain 0.829 (0.783–0.868)
 Sores cause pain 241 (0) 214 (88.8) 12 (5.0) 8 (3.3) 7 (2.9) 0.801
 Trouble swallowing 241 (0) 208 (86.3) 9 (3.7) 15 (6.2) 9 (3.7) 0.778
 Trouble speaking 240 (1) 208 (86.7) 12 (5.0) 12 (5.0) 8 (3.3) 0.780
 Sensitivity of mouth/
throat
241 (0) 197 (81.7) 19 (7.9) 14 (5.8) 11 (4.6) 0.788
 Altered food choices 241 (0) 201 (84.6) 9 (3.7) 14 (5.8) 14 (5.8) 0.811
 Difficulty brushing 
teeth
153 (0) 141 (92.2) 2 (1.3) 5 (3.3) 5 (3.3) 0.842
Mucus 0.743 (0.685–0.792)
 Mucus/phlegm 240 (1) 116 (48.3) 51 (21.3) 45 (18.8) 28 (11.7) 0.716
 Choking 241 (0) 204 (84.6) 17 (7.1) 8 (3.3) 12 (5.0) 0.685
 Difficulty swallowing 241 (0) 203 (84.2) 16 (6.6) 13 (5.4) 9 (3.7) 0.689
 Sleep affected 240 (1) 198 (82.5) 20 (8.3) 15 (6.3) 7 (2.9) 0.653
Voice/communication 0.735 (0.671–0.789)
 Trouble speaking 240 (1) 135 (56.3) 37 (15.4) 49 (20.4) 19 (7.9) 0.646
 Hoarse voice 239 (2) 97 (40.6) 59 (24.7) 48 (20.1) 35 (14.6) 0.742
 Trouble being under-
stood
238 (3) 137 (57.6) 33 (13.9) 37 (15.5) 31 (13.0) 0.544
Taste/smell 0.823 (0.786–0.856)
 Taste altered 239 (2) 140 (58.6) 31 (13.0) 41 (17.2) 27 (11.3) 0.756
 Decreased desire to eat 241 (0) 177 (73.4) 21 (8.7) 26 (10.8) 17 (7.1) 0.757
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Differences were expected when comparing patients 
with different treatment completion times, since scores 
decrease over time but do not completely resolve [18, 
26]. The analysis of the mean score of patients who had 
completed radiotherapy more than 12  months previ-
ously revealed that such scores were lower for this group, 
including in those domains where significant differences 
were not observed. However, contrary to these results, 
some studies, using questionnaires specifically developed 
for HNC (EORTC H&N 35), showed that at the 5-year 
follow up, a worsening of some symptoms, such as sense 
problems, less sexuality, dental problems, mouth opening 
and dry mouth, is revealed [27].
Using staging as a criterion for the discrimination 
among groups, the hypothesis was that patients with 
higher staging would have undergone more aggressive 
treatment, resulting in a greater symptom burden. A 
study of patients with HNC showed that patients whose 
disease was in stages III/IV had a higher symptom burden 
than those with stage I/II evaluated at 3 and 6  months, 
and this difference was less evident at 12  months [28]. 
When considering that the patients in our study are 
disease free, and that some have been followed up over 
many years, this difference was diluted in most domains, 
although the mean scores were higher in group III/IV 
than in group I/II.
Surgical criteria for group discrimination revealed sig-
nificant differences in just three domains (swallowing 
solids, trismus and teeth). It was expected that patients 
undergoing combined therapeutic procedures would 
have higher mean scores, which was confirmed in most 
domains, although this was not statistically significant. 
According to Alicikus et  al. [29], tumor site and thera-
peutic modality are the most important factors affect-
ing QoL domains, including symptoms in treated HNC 
patients.
In an additional analysis comparing disease sites, the 
instrument could discriminate between patients whose 
disease was located in the oral cavity/oropharynx and 
hypopharynx/larynx in seven domains, with statistically 
significant differences.
Analyzing domains in terms of reliability, considering 
values ≥0.7 [16], the values in this study were satisfactory 














n (%) n (%) n (%) n (%) (95 % CI)
 Altered food choices 240 (1) 181 (75.4) 20 (8.3) 23 (9.6) 16 (6.7) 0.788
 Decreased food eaten 241 (1) 167 (69.3) 28 (11.6) 31 (12.9) 15 (6.2) 0.766
 Sense of smell 
changed
240 (0) 177 (73.8) 23 (9.6) 22 (9.2) 18 (7.5) 0.853
 Altered food choices 241 (0) 219 (90.9) 9 (3.7) 9 (3.7) 4 (1.7) 0.823
Teeth 0.670 (0.573–0.749)
 Difficulty chewing 226 (1) 79 (35.0) 36 (15.9) 55 (24.3) 56 (24.8) 0.592
 Teeth sensitive to hot, 
cold, sweet foods
147 (1) 75 (51.0) 23 (15.6) 23 (15.6) 26 (17.7) 0.545
 Teeth feel looser 147 (1) 108 (73.5) 15 (10.2) 10 (6.8) 14 (9.5) 0.566
 Cracking/chipping 
teeth
147 (1) 105 (71.4) 16 (10.9) 18 (12.2) 8 (5.4) 0.683
General pain 0.820 (0.776–0.856)
 Average pain level 241 (0) 173 (71.8) 41 (17.0) 17 (7.1) 10 (4.1) 0.610
 Worst pain level 240 (1) 174 (72.5) 30 (12.5) 16 (6.7) 20 (8.3) 0.639
 Pain causing difficulty 
sleeping
240 (1) 212 (88.3) 9 (3.8) 8 (3.3) 11 (4.6) 0.927
Trismus
 Limited mouth open-
ing
241 (0) 173 (71.8) 26 (10.8) 26 (10.8) 16 (6.6) –
Neck
 Limitations in neck/
shoulder movement
241 (0) 173 (71.8) 30 (12.4) 24 (10.0) 14 (5.8) –
Hearing
 Hearing problems 241 (0) 166 (68.9) 24 (10.0) 23 (9.5) 28 (11.6) –
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solids). Those values were lower than those in the valida-
tion study of the original instrument, which ranged from 
0.70 (swallowing liquid) to 0.95 (mucus) [7]. It is known 
that domains with small numbers of items and asymmet-
ric distribution may have lower internal consistency [17].
The stability of the instrument, as measured by the 
ICC, proved to be satisfactory for most of the VHNSS 2.0 
domains except for the hearing and neck items, where 
the values were much lower than expected, suggesting 
that there may be problems in these items that prevent 
proper understanding. Further studies are necessary to 
clarify the psychometric properties of the hearing and 
neck items in different populations and evaluate the need 
for instrument modifications.
The present study has some limitations. The selected 
patients were free of disease, which may have limited 
the retest to be performed in the recommended time 
interval for all patients, and may also have affected the 
known-groups analysis, in which the ability to discrimi-
nate between groups could not be validated for certain 
domains. This resulted in a large percentage of patients, 
in some items, with very low or absent symptomatology. 
Moreover, since all the subjects were follow up patients, 
this may hinder the generalization of the findings for 
patients undergoing treatment. So, further studies should 
be carried out in this group of patients.






Nutrition 1.24 1.89 0.00 0.00 9.25
Swallowing 
solids
2.63 2.22 0.00 2.25 9.88
Swallowing 
liquids
0.86 1.74 0.00 0.00 9.00
Dry mouth 3.38 2.72 0.00 2.80 10.0
Mouth pain 0.76 1.52 0.00 0.00 7.67
Mucus 1.30 1.87 0.00 0.50 10.00
Voice 2.59 2.60 0.00 1.67 10.00
General pain 1.13 2.10 0.00 0.00 10.00
Taste/Smell 1.46 1.97 0.00 0.50 9.17
Teeth 2.37 2.28 0.00 2.00 10.00
Trismus 1.54 2.72 0.00 0.00 10.00
Neck 1.44 2.59 0.00 0.00 10.00
Hearing 1.78 3.05 0.00 0.00 10.00
Table 4 Correlation coefficient between VHNSS 2.0 and the EORTC QLQ C30 and EORTC H&N 35 (convergent validity)
VHNSS 2.0 Vanderbilt Head and Neck Cancer Symptom Survey version 2.0, : European Organization for Research and Treatment of Cancer, r Pearson’s correlation 
coefficient, 95 % CI 95 % confidence interval
* p < 0.001
a Correlations assumed a priori; the remaining correlations were additional findings
VHNSS 2.0 domains Instruments Domains/items Correlation coefficient (r) 95 % CI
Nutrition EORTC QLQ C30 Appetite loss 0.601* (0.514–0.676)
EORTC H&N 35 Social eatinga 0.537* (0.440–0.622)
Swallowing solids EORTC H&N 35 Nutritional supplements 0.667* (0.591–0.732)
EORTC H&N 35 Swallowinga 0.756* (0.696–0.805)
EORTC H&N 35 Social eating 0.648* (0.568–0.716)
Swallowing liquids EORTC H&N 35 Swallowinga 0.470* (0.365–0.563)
Dry mouth EORTC H&N 35 Swallowinga 0.597* (0.509–0.673)
EORTC H&N 35 Dry moutha 0.713* (0.645–0.770)
EORTC H&N 35 Sticky saliva 0.543* (0.447–0.627)
Mouth pain EORTC QLQ C30 Paina 0.485* (0.382–0.576)
EORTC H&N 35 Paina 0.659* (0.581–0.725)
EORTC H&N 35 Swallowing 0.578* (0.488–0.657)
EORTC H&N 35 Social eatinga 0.418* (0.308–0.518)
Mucus EORTC H&N 35 Cough 0.467* (0.362–0.560)
Voice EORTC H&N 35 Speech problemsa 0.739* (0.676–0.792)
General pain EORTC QLQ C30 Paina 0.583* (0.492–0.660)
EORTC H&N 35 Paina 0.572* (0.480–0.651)
EORTC H&N 35 Pain killers 0.545* (0.450–0.628)
Taste/smell EORTC H&N 35 Senses problemsa 0.667* (0.590–0.731)
Teeth EORTC H&N 35 Teeth 0.570* (0.449–0.670)
Trismus EORTC H&N 35 Opening moutha 0.748* (0.687–0.799)
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Additionally, due to the choice of participants, the 
entire instrument was applied by the interviewer who 
read the items aloud, a procedure that may have facili-
tated the understanding of the instrument in a popula-
tion with a mainly low education level. Hence, it would be 
important to confirm the psychometric properties, of the 
Brazilian Portuguese version, in self-administered situa-
tions. Another important limitation is that the assessment 
of responsiveness, to determine whether the instrument 
could detect changes over a time interval, was not done, 
and this would be important when the instrument is used 
in a clinical setting as an aid in the decision-making pro-
cess. VHNSS 2.0 is an instrument available only in the 
English and Portuguese languages. Thus, there are few 
studies that have used this instrument to date, hindering 
any comparison of our findings with the literature.
Conclusions
The validation process of the Brazilian Portuguese version 
VHNSS 2.0 has revealed that the instrument has adequate 
construct validity, as measured by convergent validity and 
known-groups analysis, and has acceptable internal con-
sistency for most domains. Its use will contribute to the 
identification of symptoms and oral changes in patients 
with HNC who underwent exclusive or combined radio-
therapy, thus allowing the development of strategies 
to monitor such changes. However, further studies are 
needed to assure that VHNSS 2.0 Brazilian Portuguese 
version is, beyond any reasonable doubt, a valid and reli-
able instrument to assess oral symptoms in HNC.
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